ライフサイエンスコーパス: ischemic heart disease

1 age: 68 +/- 12 years; 53.2% had a history of ischemic heart disease).

2 d cardiomyopathy and 21 patients (21.6%) had ischemic heart disease).

3 bral microbleeds, hypertension, diabetes and ischemic heart disease.

4 y for the management of patients with stable ischemic heart disease.

5 se affects almost one-third of patients with ischemic heart disease.

6 poptosis is a significant problem underlying ischemic heart disease.

7 s with acute myocardial infarction or stable ischemic heart disease.

8 Equal numbers in each group died of ischemic heart disease.

9 saved for each exposed worker who died from ischemic heart disease.

10 ing fluid was recently linked to deaths from ischemic heart disease.

11 -effectiveness of CABG versus PCI for stable ischemic heart disease.

12 0, 5,807) life-years among those who died of ischemic heart disease.

13 edical therapy alone in patients with stable ischemic heart disease.

14 of cardiac stem/progenitor cell therapy for ischemic heart disease.

15 tion of PM2.5 with circulatory mortality and ischemic heart disease.

16 ents who had both type 2 diabetes and stable ischemic heart disease.

17 and ameliorates remodeling in patients with ischemic heart disease.

18 ysis of preclinical data of cell therapy for ischemic heart disease.

19 also be confirmed in patients suffering from ischemic heart disease.

20 ticularly high rates of premature death from ischemic heart disease.

21 scular disease but one only half as great on ischemic heart disease.

22 maging immune activity in organs involved in ischemic heart disease.

23 tion report of no association between SU and ischemic heart disease.

24 duced risks of ischemic vascular disease and ischemic heart disease.

25 ve coronary angiography for suspected stable ischemic heart disease.

26 nce on mitral valve geometry and function in ischemic heart disease.

27 d rural communities for patients with stable ischemic heart disease.

28 f care and outcomes for patients with stable ischemic heart disease.

29 ancer therapy, particularly in patients with ischemic heart disease.

30 duced risks of ischemic vascular disease and ischemic heart disease.

31 greater proportionate mortality burden from ischemic heart disease.

32 nary syndromes and 2062 patients with stable ischemic heart disease.

33 tion of the myocardial injury occurring with ischemic heart disease.

34 y age, sex, time of symptom onset, and known ischemic heart disease.

35 ied more frequently of other causes, such as ischemic heart disease.

36 se hearts subjected to conditions that mimic ischemic heart disease.

37 tions, particularly in those with underlying ischemic heart disease.

38 d complementary information in patients with ischemic heart disease.

39 es to the severity of myocardial damage from ischemic heart disease.

40 iglyceride-rich lipoprotein particles causes ischemic heart disease.

41 novel diagnostic and therapeutic targets for ischemic heart disease.

42 lated with QTc prolongation in patients with ischemic heart disease.

43 reducing myocardial injury in subjects with ischemic heart disease.

44 2 could be a potential therapeutic target in ischemic heart disease.

45 ejection fraction not caused by valvular or ischemic heart disease.

46 rophy, cardio-oncology, aortic stenosis, and ischemic heart disease.

47 y and the proportion of adults with baseline ischemic heart disease.

48 larizing damaged myocardium in patients with ischemic heart disease.

49 ding those presenting early or known to have ischemic heart disease.

50 1941-1994) for mortality from all causes and ischemic heart disease.

51 iding important diagnostic information about ischemic heart diseases.

52 nterval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52).

53 1.05) for overall CVD, 0.97 (0.86, 1.09) for ischemic heart disease, 0.93 (0.81, 1.07) for stroke, 0.

54 9-1.6), 1.5 (1.2-2.0), and 2.0 (1.4-2.9) for ischemic heart disease; 1.4 (0.9-2.1), 1.2 (0.8-1.9), an

55 analyses revealed a significant increase in ischemic heart disease (10-year hazard ratio, 1.14; 95%

56 ation was observed in 30.5% of patients with ischemic heart disease: 11.3% had mild airflow limitatio

57 at the 90th and 10th percentile was 2.0 for ischemic heart disease (119.1 vs 235.7 deaths per 100000

58 nal class III (1 point) or IV (3 points); no ischemic heart disease (2 points); renal dialysis (3 poi

59 gnosed previously with these conditions (for ischemic heart disease, 26.3% compared with 43.7%; for c

60 riable odds ratio estimates were as follows: ischemic heart disease 3.30 (95% confidence interval, 2.

61 fold for myocardial infarction, 3.2-fold for ischemic heart disease, 3.2-fold for ischemic stroke, an

62 was responsible for 31% of all deaths, with ischemic heart disease (31%) and cerebrovascular disease

63 mated loss in life expectancy was related to ischemic heart disease (36% in men, 31% in women) but de

64 D as the underlying cause, including chronic ischemic heart disease (42% of CVD deaths), hypertensive

65 77%) participants were men, had a history of ischemic heart disease (56%), and were prescribed beta-b

66 .0%), and survivors were less likely to have ischemic heart disease (6.1% v 8.9%; P < .01).

67 compared with LBBB) were more likely to have ischemic heart disease (79% vs. 29%; p < 0.0001).

68 24.6%-25.4%] for those aged 80-84 years) and ischemic heart disease (8.6% [8.3%-8.9%] versus 19.0% [1

69 tion fraction who have a lower prevalence of ischemic heart disease, a less severe hemodynamic, bioma

70 We found that ischemic heart disease accounted for only 12% of the com

71 Ischemic heart disease accounted for the second-highest

72 l PM2.5 was associated with a higher risk of ischemic heart disease among aluminum manufacturing work

73 nd mortality (all-cause, cardiovascular, and ischemic heart disease) among 835 white men in the Norma

74 d concordance statistic of 0.70 and 0.70 for ischemic heart disease and 0.63 and 0.66 for stroke, res

75 ance statistics ranged from 0.66 to 0.67 for ischemic heart disease and 0.68 to 0.72 for stroke.

76 were 0.87 (95% CI: 0.78, 0.97; P = 0.01) for ischemic heart disease and 0.80 (95% CI: 0.73, 0.88; P <

77 was 0.90 (95% CI: 0.75, 1.08; P = 0.27) for ischemic heart disease and 0.88 (0.72, 1.08; P = 0.22) f

78 he equation for prognostic information about ischemic heart disease and all-cause death was evaluated

79 Secondary outcomes included 10-year ischemic heart disease and all-cause death.

80 d vegetables was associated with low risk of ischemic heart disease and all-cause mortality.

81 vegetables, are associated with low risk of ischemic heart disease and all-cause mortality.

82 ature mortality, and the leading causes were ischemic heart disease and cancer, which appeared to be

83 d diabetes were independent risk factors for ischemic heart disease and cardiomyopathy, and smoking w

84 were 2.5 times and 5.9 times more at risk of ischemic heart disease and cardiomyopathy/heart failure

85 Ischemic heart disease and cerebrovascular disease age-s

86 diomyopathy, and smoking was associated with ischemic heart disease and diabetes (odds ratios [ORs],

87 s for metabolic syndrome, and reduce risk of ischemic heart disease and diabetes.

88 We applied Cox MSMs in a study of incident ischemic heart disease and exposure to particulate matte

89 Ischemic heart disease and greater age, but not diabetes

90 erapeutic armamentarium in the fight against ischemic heart disease and heart failure.

91 e matrix metalloproteinases in patients with ischemic heart disease and HF with a reduced EF can prov

92 Ischemic heart disease and ischemic stroke comprise the

93 declines in the incidence and mortality from ischemic heart disease and ischemic stroke since the mid

94 combination-associate with increased risk of ischemic heart disease and myocardial infarction indepen

95 al population, mainly because of deaths from ischemic heart disease and other smoking-related disease

96 al protective role in the pathophysiology of ischemic heart disease and pressure-overload heart failu

97 Patients with stable ischemic heart disease and previous myocardial infarctio

98 risk of adverse outcome after adjustment for ischemic heart disease and QRS width (hazard ratio [HR]:

99 tment in improving survival in patients with ischemic heart disease and reduced ejection fraction.

100 Ischemic heart disease and stroke are the predominant ca

101 rpose We aimed to predict individual risk of ischemic heart disease and stroke in 5-year survivors of

102 Substantial differences exist between county ischemic heart disease and stroke mortality rates.

103 Results Ischemic heart disease and stroke occurred in 265 and 29

104 Ischemic heart disease and stroke remain the leading cau

105 y can predict individual risk for subsequent ischemic heart disease and stroke with reasonable accura

106 through age 50 years for the development of ischemic heart disease and stroke.

107 lence of airflow limitation in patients with ischemic heart disease and the effects on quality of lif

108 ents who had both type 2 diabetes and stable ischemic heart disease and were enrolled in the Bypass A

109 f noninvasive modalities in the detection of ischemic heart disease, and discuss nonischemic cardiomy

110 additional adjustment for diabetes mellitus, ischemic heart disease, and hypertension.

111 996 through 2013; with spending on diabetes, ischemic heart disease, and low back and neck pain accou

112 Mortality due to cardiovascular disease, ischemic heart disease, and myocardial infarction.

113 such chronic conditions as type 2 diabetes, ischemic heart disease, and some types of cancer, but th

114 ts with atrial fibrillation, cardiomyopathy, ischemic heart disease, and valvular heart disease.

115 ects, except for a subgroup of patients with ischemic heart disease as a result of severe coronary ar

116 king fluids and mortality, particularly from ischemic heart disease, as well as an instructive exampl

117 ere 45 to 83 years of age and free of HF and ischemic heart disease at baseline.

118 d our ability to understand the pathology of ischemic heart disease, atherosclerosis, and heart failu

119 ized with a principal discharge diagnosis of ischemic heart disease before (November 1, 2004, to July

120 n the prevalence, symptoms, and prognosis of ischemic heart disease between men and women.

121 verall, and 29.3% of those with a history of ischemic heart disease (both P<0.001).

122 PCI) relieves angina in patients with stable ischemic heart disease, but clinical trials have not sho

123 iated with better prognosis in patients with ischemic heart disease, but the underlying mechanisms re

124 from all cardiovascular diseases, including ischemic heart disease, cerebrovascular disease, ischemi

125 s, hypertension, dyslipidemia) and diseases (ischemic heart disease, cerebrovascular, and peripheral

126 In addition to ischemic heart disease, certain nonischemic conditions m

127 compared these results to those for cancer, ischemic heart disease, chronic obstructive pulmonary di

128 ent comorbidities, including cardiomyopathy, ischemic heart disease; chronic renal failure, with and

129 zations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent cha

130 Similarly, in the stable ischemic heart disease cohort, bivalirudin use was assoc

131 likely to have causes of death of cancer or ischemic heart disease, compared with younger elderly pa

132 ch included all Ontario patients with stable ischemic heart disease confirmed on cardiac catheterizat

133 isease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797

134 n patients with hypertrophic cardiomyopathy, ischemic heart disease, diabetes mellitus, and more.

135 0% and comorbid cardiac risk factors such as ischemic heart disease, diabetes mellitus, or hypertensi

136 openhagen were genotyped, of whom 11,984 had ischemic heart disease diagnosed between 1976 and 2010.

137 ased, including liver disease, hypertension, ischemic heart disease, disorders of lipid metabolism, a

138 Coronary arteries from patients with ischemic heart disease express large amounts of IL-1beta

139 In chronic ischemic heart disease, focal stenosis, diffuse atherosc

140 United States who were followed for incident ischemic heart disease from 1998 to 2012, and we address

141 The sample comprised 607 patients with ischemic heart disease from Holbaek Hospital, Denmark.

142 ry angiography for possible suspected stable ischemic heart disease, from October 1, 2008, to Septemb

143 Only those with prior ischemic heart disease had a significantly lower left ve

144 Ischemic heart disease has been relatively uncommon.

145 ic resonance strain imaging in patients with ischemic heart disease have been limited by sample size

146 last few decades, but mortality trends from ischemic heart disease have been more varied, with some

147 cardiac comorbidities in patients with COPD: ischemic heart disease, heart failure, and atrial fibril

148 Among patients with diabetes and stable ischemic heart disease, higher SYNTAX scores predict hig

149 larization is an effective means of treating ischemic heart disease; however, current therapeutic rev

150 favorable prognosis in patients with native ischemic heart disease; however, the impact of collatera

151 lung cancer (HR = 1.08, 95% CI: 1.02, 1.14), ischemic heart disease (HR = 1.09, 95% CI: 1.02, 1.16),

152 ension was associated with increased risk of ischemic heart disease (HR, 1.44 [95% CI, 1.24-1.68]), m

153 0.87; 95% CI: 0.76-0.99), a 26% reduction in ischemic heart disease (IHD) (RR: 0.74; 95% CI: 0.63-0.8

154 terval: 0.011, 0.393) (n = 5,818 deaths) for ischemic heart disease (IHD) after adjustment for dose f

155 vement in clinical outcomes of patients with ischemic heart disease (IHD) after ventricular tachycard

156 ation to clarify the role of birth weight in ischemic heart disease (IHD) and lipids.

157 Although emotional stress is associated with ischemic heart disease (IHD) and related clinical events

158 Ischemic heart disease (IHD) burden consists of years of

159 tion between carbohydrate intake and risk of ischemic heart disease (IHD) has not been fully explored

160 ous studies on dietary magnesium and risk of ischemic heart disease (IHD) have yielded inconsistent r

161 The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with

162 Recognition of ischemic heart disease (IHD) is often delayed or deferre

163 Ischemic heart disease (IHD) is the greatest single caus

164 Ischemic heart disease (IHD) is the leading cause of dea

165 n to cardiovascular disease (CVD) mortality, ischemic heart disease (IHD) mortality, and all-cause mo

166 iations between long-term PM2.5 exposure and ischemic heart disease (IHD) mortality, as established i

167 Ischemic heart disease (IHD) occurred in 62% of patients

168 s in morbidity and mortality attributable to ischemic heart disease (IHD) require an understanding of

169 tudies have examined differences in incident ischemic heart disease (IHD) risk between vegetarians an

170 aise the impact of risk factor confluence on ischemic heart disease (IHD) risk by testing whether gen

171 etween saturated fatty acid (SFA) intake and ischemic heart disease (IHD) risk is debated.

172 Obesity leads to increased ischemic heart disease (IHD) risk, but the risk is thoug

173 e of invasive coronary angiography in stable ischemic heart disease (IHD) varies widely.

174 To clarify the role of thyroid function in ischemic heart disease (IHD) we assessed IHD risk and ri

175 he pollutants and all-cause, cardiovascular, ischemic heart disease (IHD), and respiratory mortality.

176 cular disease (total cardiovascular disease, ischemic heart disease (IHD), and stroke) in adult women

177 including myocardial infarction (MI), other ischemic heart disease (IHD), congestive heart failure (

178 Hospital admissions for ischemic heart disease (IHD), congestive heart failure (

179 ble age-related signs associate with risk of ischemic heart disease (IHD), myocardial infarction (MI)

180 consumption of nuts and legumes and risk of ischemic heart disease (IHD), stroke, and diabetes have

181 cardiovascular outcomes were CVD [including ischemic heart disease (IHD), stroke, and vascular inter

182 depression and Alzheimer's disease, but not ischemic heart disease (IHD).

183 red with that in nonstented patients without ischemic heart disease (IHD).

184 ejection fraction overall and in relation to ischemic heart disease (IHD).

185 left ventricular mass (LVM) in patients with ischemic heart disease (IHD).

186 s), has been associated with a lower risk of ischemic heart disease (IHD).

187 rheumatoid arthritis (RA) is independent of ischemic heart disease (IHD).

188 Ischemic and/or non-ischemic heart diseases (IHD and/or NIHD) were detected

189 ques in coronary arteries from patients with ischemic heart disease implying a role in human arterial

190 Physicians have traditionally viewed ischemic heart disease in a cardiocentric manner: plaque

191 mained a significant predictor of asthma and ischemic heart disease in most bipollutant models.

192 sumption is associated with a higher risk of ischemic heart disease in patients with diabetes.

193 ations have been associated with low risk of ischemic heart disease in prospective studies, but resul

194 M2.5 exposure increases the risk of incident ischemic heart disease in workers in both aluminum smelt

195 n, coronary revascularization, or death from ischemic heart disease) in 2168 women who underwent radi

196 nant cholesterol is a causal risk factor for ischemic heart disease independent of reduced high-densi

197 s associated with a 2.8-fold causal risk for ischemic heart disease, independent of reduced HDL chole

198 d into 2 documents addressing ACS and stable ischemic heart disease individually.

199 hallmark of many diseases, including cancer, ischemic heart disease, inflammation, and others.

200 l incidence rate (IR) for each condition are ischemic heart disease, IR=1518.7; myocardial infarction

201 Ischemic heart disease is a complex disease process caus

202 ure with reduced ejection fraction caused by ischemic heart disease is associated with increased morb

203 Ischemic heart disease is characterized by contractile d

204 Risk stratification in patients with stable ischemic heart disease is essential to guide treatment d

205 the prevalence of angina and mortality from ischemic heart disease is higher for women than men.

206 Ischemic heart disease is rapidly growing as the common

207 Ischemic heart disease is the leading cause of death glo

208 eart failure due to cardiomyocyte loss after ischemic heart disease is the leading cause of death in

209 Ischemic heart disease is the leading cause of heart fai

210 Ischemic heart disease is the number one cause of death

211 t of this exposure on the subsequent risk of ischemic heart disease is uncertain.

212 risk of developing cardiovascular diseases (ischemic heart disease, ischemic stroke), metabolic dise

213 OPD) exacerbations, pneumonias, lung cancer, ischemic heart disease, ischemic stroke, and all-cause m

214 Its major clinical manifestations include ischemic heart disease, ischemic stroke, and peripheral

215 e risk of first fatal or nonfatal CVD event (ischemic heart disease, ischemic stroke, heart failure,

216 Heart samples from ischemic heart disease (ISHD) patients served as heart f

217 dalities for the diagnosis and management of ischemic heart disease, it is important for radiologists

218 The prevalence of these ischemic heart disease levels in fractional flow reserve

219 condition categories (eg, diabetes mellitus, ischemic heart disease, liver disease).

220 to be younger, men, have diabetes mellitus, ischemic heart disease, lower left ventricular ejection

221 1.1%-3.6%) and 6.9% (95% CI, 4.0%-9.9%) for ischemic heart disease mortality among adults 65 years a

222 Ischemic heart disease mortality and long-term exposure

223 The association between coal use and ischemic heart disease mortality diminished with increas

224 An overall trend for reduction in ischemic heart disease mortality was observed, most pron

225 .81, 1.07) for stroke, 0.98 (0.77, 1.24) for ischemic heart disease mortality, 0.92 (0.56, 1.50) for

226 86, 4.68) for all-cause, cardiovascular, and ischemic heart disease mortality, respectively.

227 men compared with men, with similar risk for ischemic heart disease mortality.

228 , O3, and NO2 was positively associated with ischemic heart disease mortality.

229 Mortality rates (MRs) for each condition are ischemic heart disease, MR=105.5; ischemic stroke, MR=42

230 rs at exacerbation were higher in those with ischemic heart disease (n = 12) than those without (n =

231 Twenty sepsis patients, 11 ischemic heart disease, nine dilated cardiomyopathy, and

232 s between ingestion of inorganic arsenic and ischemic heart disease, nonmalignant respiratory disease

233 Ischemic heart disease (odds ratio [OR], 7.21; P < 0.001

234 HF was higher in patients with a history of ischemic heart disease or atrial fibrillation.

235 Among all people who died from ischemic heart disease or cancer, schizophrenia patients

236 r filtration rate, age, history of diabetes, ischemic heart disease or hypertension, Killip class, le

237 aged 45 to 79 years, with no history of HF, ischemic heart disease, or cancer at baseline.

238 altered abundance in septic cardiomyopathy, ischemic heart disease, or dilated cardiomyopathy, in co

239 did not differ according to age, race, prior ischemic heart disease, or ejection fraction (all intera

240 and the coexistence of atrial fibrillation, ischemic heart disease, or hypertensive cardiopathy.

241 defined as a history of atrial fibrillation, ischemic heart diseases, or congestive heart failure.

242 cancer (HR = 1.14; 95% CI: 1.03, 1.27), and ischemic heart disease (overall HR = 1.61; 95% CI: 1.14,

243 m peripheral vascular disease (P = 0.02) and ischemic heart disease (P = 0.001).

244 ilar to those for risk of cancer (p = .002), ischemic heart disease (p = 4 x 10(-99)), chronic obstru

245 EBW occurred most often in ischemic heart disease patients (N=114, 49%) compared wi

246 genetic variants near IRF2BP2 associate with ischemic heart disease progression in humans.

247 1 year, cardiac-related death, hypertension, ischemic heart disease, pulmonary circulation problems,

248 n (COURAGE) trial, some patients with stable ischemic heart disease randomized to optimal medical the

249 Ischemic heart disease remains rare in most countries.

250 y syndrome (ACS), the acute manifestation of ischemic heart disease, remains a major cause of morbidi

251 Ischemic heart disease resulting from myocardial infarct

252 (rate ratio [RR], 1.14; 95% CI, 1.13-1.14), ischemic heart disease (RR, 1.11; 95% CI, 1.10-1.11), ma

253 (rate ratio [RR], 1.62; 95% CI, 1.20-21.8), ischemic heart disease (RR, 4.31; 95% CI, 3.38-5.49), an

254 ), asthma (RR=1.12, 95% CI: 1.03, 1.22), and ischemic heart disease (RR=1.19, 95% CI: 1.03, 1.38).

255 Autologous and allogeneic cell therapy for ischemic heart disease show a similar improvement in lef

256 prediction model including QRS duration and ischemic heart disease significantly improved the net re

257 -world population among subjects with stable ischemic heart disease (SIHD) and acute coronary syndrom

258 tor (FGF)-23 identifies patients with stable ischemic heart disease (SIHD) at high risk of cardiovasc

259 neous coronary intervention (PCI) for stable ischemic heart disease (SIHD) declined after publication

260 All patients with stable ischemic heart disease (SIHD) should be managed with gui

261 of common clinical presentations for stable ischemic heart disease (SIHD) to consider use of stress

262 long-term prognosis in patients with stable ischemic heart disease (SIHD).

263 atures such as age, history of arrhythmia or ischemic heart disease, size of goiter, and severity of

264 Cardiovascular diseases (CVDs), including ischemic heart disease, stroke, and heart failure, are w

265 rtension, diabetes mellitus, hyperlipidemia, ischemic heart disease, stroke, total cholesterol level,

266 ween acute myocardial Infarction and chronic ischemic heart disease subgroups.

267 More people die every year from ischemic heart disease than any other disease.

268 in patients with congestive heart failure or ischemic heart disease than in those without (P = 0.021

269 in patients with congestive heart failure or ischemic heart disease than in those without (P = 0.021

270 the existence of differentiated patterns of ischemic heart disease that combine focal and diffuse co

271 ts with systolic heart failure not caused by ischemic heart disease, the association between the ICD

272 between urban and rural patients with stable ischemic heart disease, there were no outcome difference

273 TSD) is associated with an increased risk of ischemic heart disease, though the pathophysiologic mech

274 ogenic precursors link coronary anomalies to ischemic heart disease.Though coronary arteries are cruc

275 uggest that soy foods can potentially reduce ischemic heart disease through multiple mechanisms.

276 randomly assigned 2287 patients with stable ischemic heart disease to an initial management strategy

277 phases of the disease, potentially allowing ischemic heart disease to be tracked during a patient's

278 t they might be used in patients with stable ischemic heart disease to identify those at high risk fo

279 , including individual data of patients with ischemic heart disease treated with cell therapy.

280 elevation acute coronary syndromes or stable ischemic heart disease undergoing percutaneous coronary

281 ty of mitral regurgitation, 67 patients with ischemic heart disease underwent cardiac magnetic resona

282 rtality ratios and absolute excess risks for ischemic heart disease, valvular heart disease, and card

283 ar disease such as congestive heart failure, ischemic heart disease, valvular heart disease, pulmonar

284 Ischemic heart disease was present in 72% of patients.

285 ntative sample of 50 patients with suspected ischemic heart disease was retrospectively selected from

286 Among the four health outcomes examined, ischemic heart disease was the greatest cause of death.

287 cells in immunosuppressed animals with acute ischemic heart disease, we previously showed that these

288 y, peripheral neuropathy, diabetic foot, and ischemic heart disease were 21.9%, 17.6%, 28.0%, 6.2%, a

289 creatinine level, black race, older age, and ischemic heart disease were associated with troponin ele

290 in acute coronary syndromes (ACS) and stable ischemic heart disease were combined into 1 document.

291 incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as

292 tissue samples from patients suffering from ischemic heart disease were used to validate our finding

293 d exertional E/e' >13), excluding those with ischemic heart disease, were recruited in a tertiary car

294 gly recognized as an elementary component of ischemic heart disease, which can be accurately assessed

295 examining the proportion of patients without ischemic heart disease who were on a high-dose statin.

296 Among the 3,103 patients with ischemic heart disease who were recruited, lung function

297 elevation acute coronary syndromes or stable ischemic heart disease, who underwent percutaneous coron

298 significant in the pathophysiology of human ischemic heart disease with a preservative role in maint

299 ted myocardium, even in patients with stable ischemic heart disease with preserved LV ejection fracti

300 dox is an observation of a low prevalence of ischemic heart disease, with high intakes of saturated f